Conclusion

While clinical demand drives the field of interventional nuclear medicine and its section of radioguided surgery, technological innovations play an instrumental part in the progression of these efforts. The availability of radiotracers plays a crucial role in refining the existing procedures and expanding radioguidance to other indications. Here we can observe an increasing shift towards hybrid tracer designs, where the radiotracers, next to a radioisotope, also contain an alternative imaging label e.g. for fluorescence imaging. Next to the radiopharmaceutical advances, significant strides have been made in engineering of hardware and software. Through engineering efforts, modalities have become available for non-^99mTc radionuclides (e.g. ⁹⁰Y), and modalities have been designed for specialist surgical procedures e.g. robotic surgery. At the same time, the surgical roadmaps provided by nuclear medicine are increasingly being used to provide surgeons with augmented-, mixed- or virtual-reality displays that support navigation during radioguidance procedures.